Background: The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy. This study aims to explore the real-world efficacy and safety of 5-FU/LV-nal-IRI.
Methods: This is a retrospective multicenter analysis including advPDAC patients receiving 5-FU/LV-nal-IRI after failure of gemcitabine-based therapy. Survival analyses were performed using Kaplan-Meier method, univariate and multivariate analyses by Cox regression.
Results: A total of 296 patients (median age 64.4 years, ECOG PS ≥1 in 56% of cases) were treated at 11 Italian institutions between 2016 and 2018. 34% of them underwent primary tumor resection, and 79% received gemcitabine-nabpaclitaxel as first line. 5-FU/LV-nal-IRI was administered as second-line in 73% of cases. Objective response and disease control rate were 12% and 41%, respectively. Treatment was well tolerated with dose reductions in 50% of patients but no one permanent discontinuation; the commonest grade ≥3 toxicities were neutropenia (14%) and diarrhea (12%). Median PFS and OS from 5-FU/LV-nal-IRI initiation was 3.2 and 7.1 months, respectively.
Conclusions: These real-world data confirm the 5-FU/LV-nal-IRI efficacy and safety in advPDAC patients progressed to gemcitabine-based therapy, with outcomes comparable to NAPOLI-1, even in a less-selected population and with more modern therapeutic algorithm.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358242 | PMC |
| http://dx.doi.org/10.1002/cam4.6111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TRIM59/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway.
Cell Death Dis
December 2024
Department of Hepatobiliary Pancreatic Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, 518116, P. R. China.
Pancreatic cancer (PC) is one of the most lethal malignant tumors that lacks effective treatment, and gemcitabine-based chemoresistance occurs frequently. Therefore, new therapeutic strategies for PC are urgently needed. Tripartite motif containing 59 (TRIM59) plays an important role in breast and lung cancer chemoresistance.
View Article and Find Full Text PDFSuperior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis.
Front Oncol
November 2024
Eastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.
Background: Advanced biliary tract cancer (BTC) is associated with a poor prognosis and limited options for second-line treatment. The TOPAZ-1 and KEYNOTE-966 trials have demonstrated the benefits of combining immune checkpoint inhibitors (ICIs) with chemotherapy in treating BTC. However, the efficacy of FOLFOX as a second-line therapy is limited, highlighting the need for more effective treatment approaches.
View Article and Find Full Text PDFChemotherapy and radiotherapy for advanced pancreatic cancer.
Cochrane Database Syst Rev
December 2024
Medical Oncology, The Kinghorn Cancer Care Centre, St Vincent's Hospital, Sydney, Australia.
Article Synopsis
- Pancreatic cancer is a highly lethal disease with limited treatment options, leading to an updated review of randomized data focused on first-line treatments for advanced cases.
- The review examines the impact of chemotherapy, radiotherapy, or a combination of both on overall survival, severe adverse events, and quality of life for patients with unresectable or metastatic pancreatic cancer.
- A total of 75 studies were analyzed, with 51 included in the meta-analysis, examining various treatment comparisons and finding that the studies generally had low risks for biases in methodology.
Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.
J Gastroenterol
November 2024
Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Background: S-1 monotherapy had previously been widely used as a second-line treatment for pancreatic cancer (PC) after gemcitabine-based chemotherapy mainly in Japan. Based on the results of the NAPOLI-1 trial, the recommended second-line therapy is now liposomal irinotecan plus fluorouracil/folinic acid (nal-IRI + 5-FU/LV). However, there have been no studies comparing nal-IRI + 5-FU/LV therapy with S-1 monotherapy.
View Article and Find Full Text PDFstokes extract, a traditional herbal medicine, combined with first-line chemotherapy for unresectable locally advanced and metastatic pancreatic cancer: a prospective observational pilot study.
Front Oncol
November 2024
Department of Korean Internal Medicine, Kyung Hee University College of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
Article Synopsis
- Pancreatic cancer is highly lethal with few treatment options, leading researchers to explore traditional herbal medicines like Stokes (RVS) as potential complementary therapies to standard chemotherapy.
- A study involving 25 patients receiving RVS alongside first-line chemotherapy for inoperable advanced pancreatic cancer examined the treatment's safety and effectiveness over 20 months, focusing on outcomes like overall response rate (ORR) and disease control rate (DCR).
- Results indicated that RVS had a favorable safety profile with minimal side effects, while the median progression-free survival (PFS) was 7.24 months and overall survival (OS) was 13.9 months, suggesting it could be a safe addition to conventional treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!